BiPER Therapeutics
French tech company | Builders Republic
About
Preclinical biotech developing first-in-class small-molecule drugs for gastrointestinal cancers — its lead candidate blocks BiP/GRP78, a protein cancer cells rely on to survive, triggering tumor-cell death through endoplasmic-reticulum stress, with a clinical trial application planned for digestive cancers.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2022
- City
- STRASBOURG
- Region
- Grand Est
- Tracked rounds
- 1
- Amount raised
- 1.0 M€ raised since 2020
Funding rounds
- Seed — 2025
Investors
- Medin Fund Management